The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
Open accessAbstract
Purpose: To evaluate induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy versus up-front surgery and postoperative radiotherapy in patients with locally advanced resectable oral squamous cell carcinoma (OSCC). Patients and Methods: A prospective open-label phase III trial was conducted. Eligibility criteria included untreated stage III or IVA locally advanced resectable OSCC. Patients received two cycles of TPF induction chemotherapy (docetaxel 75 mg/m 2 on day 1, cisplatin 75 mg/m 2 on day 1, and fluorouracil 750 mg/m 2 on days 1 to 5) followed by radical surgery and postoperative radiotherapy (54 to 66 Gy) versus up-front radical surgery and postoperative radiotherapy. The primary end point was overall survival (OS). Secondary end points included local control and safety. Results: Of the 256 patients enrolled onto this trial, 222 completed the full treatment protocol. There were no unexpected toxicities, and induction chemotherapy did not increase perioperative morbidity. The clinical response rate to induction chemotherapy was 80.6%. After a median follow-up of 30 months, there was no significant difference in OS (hazard ratio [HR], 0.977; 95% CI, 0.634 to 1.507; P = .918) or disease-free survival (HR, 0.974; 95% CI, 0.654 to 1.45; P = .897) between patients treated with and without TPF induction. Patients in the induction chemotherapy arm with a clinical response or favorable pathologic response (≤ 10% viable tumor cells) had superior OS and locoregional and distant control. Conclusion: Our study failed to demonstrate that TPF induction chemotherapy improves survival compared with up-front surgery in patients with resectable stage III or IVA OSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,269
Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J.-L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032641 · Cited by 3,192
Petersen, P. E. (2003) · Community Dentistry and Oral Epidemiology · doi:10.1046/j..2003.com122.x · Cited by 3,166
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070956 · Cited by 1,705
Oral Cancer and Precancerous Lesions
Neville, B. W., & Day, T. A. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.4.195 · Cited by 1,407
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,360
Lefebvre, J.-L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Collette, L., & Sahmoud, T. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.13.890 · Cited by 1,334
Single Nucleotide Polymorphism in the Aetiology of Caries: Systematic Literature Review
Piekoszewska-Ziętek, P., Turska-Szybka, A., & Olczak-Kowalczyk, D. (2017) · Caries Research · doi:10.1159/000476075 · Cited by 1,005
Pignon, J. P., Bourhis, J., Domenge, C., & Designe, L. (2001) · Cancer/Radiothérapie · doi:10.1016/s1278-3218(00)00073-1 · Cited by 700
Kumar, B., Cordell, K. G., Lee, J. S., Worden, F. P., Prince, M. E., Tran, H. H., Wolf, G. T., Urba, S. G., Chepeha, D. B., Teknos, T. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7662 · Cited by 612
Self-citationLorch, J. H., Goloubeva, O., Haddad, R. I., Cullen, K., Sarlis, N., Tishler, R., Tan, M., Fasciano, J., Sammartino, D. E., & Posner, M. R. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70279-5 · Cited by 448
Brockstein, B., Haraf, D. J., Rademaker, A. W., Kies, M. S., Stenson, K. M., Rosen, F., Mittal, B. B., Pelzer, H., Fung, B. B., Witt, M.-E., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh308 · Cited by 370
Self-citationPrimary Chemotherapy in Resectable Oral Cavity Squamous Cell Cancer: A Randomized Controlled Trial
Licitra, L., Grandi, C., Guzzo, M., Mariani, L., Vullo, S. L., Valvo, F., Quattrone, P., Valagussa, P., Bonadonna, G., Molinari, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.146 · Cited by 321
Kademani, D. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.7.878 · Cited by 310
Long-term Quality of Life After Treatment of Laryngeal Cancer
Terrell, J. E., Fisher, S. G., & Wolf, G. T. (1998) · Archives of Otolaryngology–Head & Neck Surgery · doi:10.1001/archotol.124.9.964 · Cited by 290
Temam, S., Flahault, A., Périé, S., Monceaux, G., Coulet, F., Callard, P., Bernaudin, J., Guily, J. L. S., & Fouret, P. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.385 · Cited by 153
Perrone, F., Bossi, P., Cortelazzi, B., Locati, L. D., Quattrone, P., Pierotti, M. A., Pilotti, S., & Licitra, L. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4170 · Cited by 137
Cited by
Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions
Chinn, S. B., & Myers, J. N. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2929 · Cited by 412
Self-citationLacas, B., Carmel, A., Landais, C., Wong, S. J., Licitra, L., Tobias, J. S., Burtness, B., Ghi, M. G., Cohen, E. E. W., Grau, C., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.01.013 · Cited by 389
Self-citationMao, L., Xiao, Y., Yang, Q.-C., Yang, S.-C., Yang, L.-L., & Sun, Z.-J. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105472 · Cited by 68
Metadata
- Authors
- Zhong, L.-P., Zhang, C.-P., Ren, G.-X., Guo, W., William, W. N., Sun, J., Zhu, H.-G., Tu, W.-Y., Li, J., Cai, Y.-L., Wang, L.-Z., Fan, X.-D., Wang, Z.-H., Hu, Y.-J., Ji, T., Yang, W.-J., Ye, W.-M., Li, J., He, Y., Wang, Y.-A., Xu, L.-Q., Wang, B.-S., Kies, M. S., Lee, J. J., Myers, J. N., & Zhang, Z.-Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-02-20
- Volume
- 31
- Issue
- 6
- Pages
- 744-751
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123027910
- Cited by
- 394
- References
- 23
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.